The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)
Lung Cancer Mar 22, 2018
Muley T, et al. - Given that tumor biomarkers cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) are prognostic in early-stage non-small cell lung cancer (NSCLC), their role in predicting patients who can benefit from adjuvant chemotherapy (CTx) was determined herein. In the clinical decision making regarding which patients with squamous cell carcinoma should receive adjuvant CTx, baseline CYFRA 21-1 and CEA levels may prove to be helpful by providing further information in this regard.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
